<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Therapeutic options for children with de novo or secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (MDSs) are limited </plain></SENT>
<SENT sid="1" pm="."><plain>We report the outcome of eight pediatric patients (median age 12 years, range 3 to 19 years) with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> who underwent allogeneic bone marrow transplantation between 1984 and 1987 </plain></SENT>
<SENT sid="2" pm="."><plain>Two of the eight children had developed secondary <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> after <z:chebi fb="0" ids="22333">alkylating agent</z:chebi>-based combination chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Five patients had clonal chromosomal abnormalities, including four patients with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 </plain></SENT>
<SENT sid="4" pm="."><plain>Seven of eight patients engrafted </plain></SENT>
<SENT sid="5" pm="."><plain>Two of these seven subsequently died of complications of <z:hpo ids='HP_0011009'>acute</z:hpo> or <z:hpo ids='HP_0011010'>chronic</z:hpo> graft-v-host disease (GVHD), and a third patient died at 21 months of <z:hpo ids='HP_0002206'>pulmonary fibrosis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>None of the patients have had recurrence of disease </plain></SENT>
<SENT sid="7" pm="."><plain>The four surviving patients remain in complete remission at a median follow-up of 19 months (range 10 to 44 months) </plain></SENT>
</text></document>